incidence of severe
ly in Peru.
y C. Morrison ⁴
dad Peruana
ropical Medicine,
c Health and
Medicine,

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

31 Abstract

Background: Dengue poses a significant public health challenge in Peru and other endemic countries
worldwide. While severe dengue is known to be associated with secondary infection at the individual
level, the factors that elevate the risk of severe dengue at the population level remain poorly understood.
This study leverages over 16 years of secondary data from a Peruvian dengue surveillance system to
assess which type of serotype-specific circulation is associated with an increased risk of cumulative
incidence of severe dengue or dengue with warning signs (SD-DWS).

38 Methodology: This is a retrospective analysis of secondary data using the Peruvian Ministry of Health 39 databases of dengue cases and serotyping. A mixed negative binomial regression model for repeated 40 measures over time was employed to estimate the association between the cumulative incidence of 41 reported SD-DWS cases per 100,000 inhabitants and serotype-specific circulation. Crude and adjusted 42 incidence ratios (IRR) were estimated.

43 Principal findings: The study analyzed data from 2007 to 2022 across 19 regions of Peru, totaling 304 44 region-years. Data from nearly 58,000 serotype identification reports and 57,966 cases of SD-DWS 45 were analyzed. The regions with most cumulative incidence of SD-DWS per 100,000 inhabitants during 46 2007 to 2022 were Madre de Dios (3859), Loreto (1518), Ucayali (1492), Tumbes (1335), and Piura 47 (722). The adjusted model revealed a higher risk of cumulative incidence of SD-DWS when there was 48 specific circulation of DENV-123 (aIRR 7.57 CI 4.00 – 14.31), DENV-12 (aIRR 4.66 CI 2.57 – 8.44), 49 DENV-23 (aIRR 3.55 CI 1.75 – 7.21), or when there was circulation of DENV-2 alone or co-circulating 50 with other serotypes (aIRR 27.7 CI 15.46 -49.63).

51 Conclusions: Circulation of DENV-2 was associated with higher average incidence rate ratios of SD52 DWS.

- 53 Keywords: Dengue, Serotypes, dengue severity.
- 54
- 55
- ---
- 56
- 57

58 Author summary

59	We investigated how the circulation of different dengue virus (DENV) serotypes are associated
60	with the incidence of severe dengue and dengue with warning signs in Peru, a country where dengue is
61	endemic. We analyzed 16 years of data from the dengue surveillance system, including nearly 58,000
62	serotype identification reports and 57,966 cases of severe dengue and dengue with warning signs. We
63	found that regions with specific circulation of DENV-2, either alone or in combination with other
64	serotypes, had higher incidence rates of severe dengue and dengue with warning signs. Our findings
65	highlight the importance of monitoring DENV serotype circulation to manage and prevent severe
66	dengue, especially in regions where DENV-2 is prevalent.
67	
68	
69	
70	
71	
72	
73	
74	
75	
76	
77	
78	
79	
80	
81	
82	

83 Introduction

Dengue, a significant public health issue, is endemic in Peru, as in other tropical climates. It is
caused by an RNA virus with four known serotypes (DENV-1, DENV-2, DENV-3, and DENV-4) [1].
The dengue virus (DENV) is primarily transmitted through the bite of an infected female mosquito of
the *Aedes* genus: in Peru, it is mainly transmitted by *Aedes aegypti* [2,3].

Most of the dengue research in Peru has been carried out in the Amazonian city of Iquitos. These studies have shown that since the reintroduction of dengue in Peru in 1990, all four DENV serotypes (including the introduction of new genotypes) have circulated [4–6]. In addition, Peru has experienced several epidemic outbreaks (2001/2002, 2011/2012, 2017, and 2023) with a high number of cases of severe dengue (SD) or dengue with warning signs (DWS) (SD-DWS), sometimes overwhelming or collapsing health systems [2,7].

94 For an individual, a secondary DENV infection with a heterologous serotype is one of the 95 primary risk factors for severe dengue [8-12]. At the population level, the risk of severe disease may 96 be associated with 1) an increase in the population susceptible to second infections, 2) the sequential or 97 co-circulation of multiple DENV serotypes [13], and 3) a rise in the overall force of infection, increasing 98 the number of all cases across the clinical spectrum of disease and the probability that individuals 99 susceptible to a second infection become infected. Additionally, inadequate disease surveillance and 100 vector control, inadequate or improper case management, all contribute to the public health 101 consequences of dengue outbreaks, and particularly, of severe disease.

Due to the low prevalence of severe dengue (less than 1% of total dengue cases [3]), identification of specific risk factors for SD-DWS requires multiple years (decades) of surveillance to achieve adequate statistical power for analyses. Our study leverages 16 years of Peruvian dengue surveillance system data to evaluate potential serotype-related risk factors (what and how many serotypes are circulating) associated with increased incidence of SD-DWS.

107

108 Methods

109 Ethics statement

Our secondary data protocol was approved by the institutional review board of the Peruvian
University Cayetano Heredia (SIDISI 207993, approval record number 079-01-22). The anonymized
data was obtained through the public information system of the Peruvian Ministry of Health.

113

114 **Data sources**

115 Data was acquired from the National Center for Epidemiology of Peru (CDC-Peru), a branch 116 of the Ministry of Health. We extracted all reported dengue cases and serotyping data collected between 117 2007 and 2022. Reporting of dengue cases is mandatory for both public and private health centers 118 nationwide [14]. This surveillance system reports both confirmed and probable cases. Confirmed cases 119 are those with laboratory confirmation by DENV isolation, RT-PCR, NS1 antigen, detection of IgM 120 antibodies for dengue in a single sample, and/or evidence of IgM seroconversion in paired samples. 121 Probable cases correspond to those that occur during outbreaks, meet case definitions set by the World 122 Health Organization [15] or by epidemiological link for patients who had direct contact with confirmed 123 cases [14]. Overall, 90% of cases in our database were classified as confirmed and 10% represented 124 probable cases.

A small proportion of these confirmed cases are analyzed in regional reference laboratories to identify the circulating serotype using multiplex RT-PCR [16]. Subsequently, the serotype identification reports are registered in the database system of the Peruvian Public Health Laboratory Network (NETLAB) [17] of the Ministry of Health. Dengue case data and serotype identification data were requested from the Ministry of Health through their public access website [18].

130

131 Study variables

Our principal outcome variable was the cumulative incidence of SD-DWS per 100,000inhabitants, associated with explanatory serotype-specific circulation variables. We calculated the

134 cumulative incidence of SD-DWS per 100,000 inhabitants for each region and year by dividing the total 135 number of SD-DWS by the projected population, estimated by year by the National Institute of Statistics 136 and Informatics (INEI) using census data. We also estimated a global summary of the cumulative 137 incidence of SD-DWS per 100,000 inhabitants for each region over the 16-year study period, by 138 dividing - per region (Peruvian state) - the total number of SD-DWS cases by the average annual 139 projected population. Serotype-specific circulation variables were created based on the total possible 140 combinations of each serotype detected per region, or their combination (DENV-1, DENV-2, DENV-141 3, DENV-4, DENV-12, DENV-13, DENV-14, DENV-23, DENV-24, DENV-34, DENV-123, DENV-142 124, DENV-134, DENV-234, and DENV-1234). Each of these variables were coded as 0, if there was 143 no presence of circulation, or 1, if there was specific presence of such circulation. Additionally, to assess 144 which serotype type has the highest risk for elevated cumulative DS-DWS incidence, we created 4 145 additional variables (circulation of DENV-1 or its combination, circulation of DENV-2 or its 146 combination, circulation of DENV-3 or its combination, and circulation of DENV-4 or its combination). 147 Additionally, for each region, we adjusted for poverty level and total number of primary care health facilities per population. The poverty level indicator was based on the INEI categorization of 148 149 "poverty with at least one unmet basic need". A family is "poor" if it has at least 1 of the following 150 characteristics: 1) home with inadequate construction (exterior walls made of straw mats or "quincha", 151 or stone with mud or wood, and dirt floor), 2) overcrowded home (more than 3 to 4 people per room), 152 3) home without indoor plumbing, 4) home with children who do not attend school, and 5) home with

high economic dependence [19].

Regarding number of health facilities, in Peru there are 3 levels of health facilities based on the complexity of the care and services: 1) primary care facilities, 2) general hospitals or clinics, 3) specialized hospitals and institutes (e.g., national oncological institute) [20]. We extracted the total number of primary care facilities per region from the Ministry of Health databases [18]. During outbreaks, primary care facilities provide care to patients suspected of dengue, provide basic care, and prevent progression to severe forms of the disease. Finally, per region, the total number of primary health facilities was divided by the projected population.

162 **Population and inclusion/exclusion criteria**

163 The study population consisted of Peruvian regions (states) with reports of SD and/or DWS and 164 dengue serotype identification from 2007 to 2022. Regions without reports of SD-DWS cases and 165 without identification of circulating serotypes were excluded from the analysis.

166

167 Analytical Approach

168 For the descriptive analysis, we created summary tables and trend graphs of our variables of 169 interest. For the main analysis, we explored the association between the cumulative incidence of SD-170 DWS per 100,000 inhabitants with each of 16 possible combinations of serotype circulation (see study 171 variable description above). In a second approach, we explored the association of SD-DWS per 172 1000,000 inhabitants by the 4 variables that indicated the circulation of each serotype or its combination. 173 For both analyses, we considered confounding adjustment variables (defined a priori by 174 epidemiological criteria), such as the poverty level variable (at the region-year level) and the number 175 of primary health centers per population per region. Given that our outcome variable had 176 overdispersion, we used mixed negative binomial regression models for repeated measures over time 177 [21] to estimate crude and adjusted cumulative incidence ratios (IRR) using the "menbreg" command 178 in Stata (versión 17.0, StataCorp LLC, College Station, TX), for this we also evaluated multicollinearity 179 among the predictors. The analyses will be performed with a significance level (α) of 0.05 and a 180 confidence level of 95%. The statistical programs used were Stata and R software (version 4.3.2.). 181

- 182
- 183
- 184
- 185

186 **Results**

187 Overall, 19 regions met our inclusion criteria for the years 2007 to 2022, for a total of 304
188 region-years included in our analysis. Five regions (Apurímac, Arequipa, Huancavelica, Moquegua,
189 and Tacna) were excluded from the analysis because they either had no reports of SD-DWS cases or no
190 serotype information was available.

191

192 Dengue cases and cumulative incidence of SD-DWS

Five regions account for 65% of reported dengue cases, and almost 80% of both DWS and SD in Peru (Table 1). Based on WHO definitions, 87.1%, 12.5%, and only 0.4% were classified as dengue without warning signs, DWS, and SD, respectively (Table 1). Some of the regions with highest cumulative dengue incidence were different than those with highest absolute numbers, with four having greater than 1,334 cases of SD-DWS per 100,000 inhabitants (Table 2 and Fig 1).

198


Regions	Dengue without warning signs	Dengue with warning signs	Dengue severe	Total cases of dengue	Percent by region
Piura	98,293	13,266	330	111,889	24.9%
Loreto	67,712	14,188	517	82,417	18.3%
Ucayali	30,910	7,442	305	38,657	8.6%
Madre de Dios	25,912	5,342	257	31,511	7.0%
San Martín	21,651	4,218	146	26,015	5.8%
Ica	21,167	601	33	21,801	4.9%
Tumbes	20,751	3,015	31	23,797	5.3%
Junín	16,295	2,039	65	18,399	4.1%
La Libertad	15,653	950	36	16,639	3.7%
Cajamarca	13,494	1,870	36	15,400	3.4%
Lambayeque	13,148	231	28	13,407	3.0%
Cusco	10,177	271	22	10,470	2.3%
Amazonas	9,562	509	38	10,109	2.3%
Ayacucho	8,603	270	20	8,893	2.0%
Huánuco	7,087	1,042	33	8,162	1.8%
Ancash	6,069	300	20	6,389	1.4%
Lima	3,544	265	5	3,814	0.9%
Pasco	1,714	205	17	1,936	0.4%
Puno	175	3	0	178	0.04%
Total	391,917	56,027	1,939	110 992	1000/
N (%)	(87.1%)	(12.5%)	(0.4%)	449,883	100%

199 Table 1. Reported dengue cases by WHO classification by region from 2007 to 2022

201 Table 2. Cumulative incidence of severe dengue and dengue with warning signs (SD-DWS) per

100,000 inhabitants from 2007 to 2022

Regions	Average population	SD-DWS cases	Cumulative incidence per 100,000 inhabitants
Madre de Dios	145,078	5,599	3,859
Loreto	968,879	14,705	1,518
Ucayali	519,088	7,747	1,492
Tumbes	228,246	3,046	1,335
Piura	188,2302	13,596	722
San Martín	825,404	4,364	529
Junín	130,9566	2,104	161
Huánuco	763,715	1,075	141
Cajamarca	143,2905	1,906	133
Amazonas	413,967	547	132
Pasco	275,340	222	81
Ica	855,401	634	74
La Libertad	1,838,790	986	53
Ayacucho	652,514	290	44
Ancash	1,129,717	320	28
Cusco	1,278,655	293	23
Lambayeque	1,221,466	259	21
Lima	9,603,276	270	3
Puno	1,253,074	3	<1
Total Average	26,597,384	57,966	218



211

Figure 1. Cumulative incidence of SD-DWS per 100,000 inhabitants by region from 2007 to
2022

214

215 Serotype circulation

From 2007 to 2022, 58,748 samples were serotyped (14.5% of laboratory-confirmed dengue cases) and registered in the NETLAB-INS system. During the observation period, DENV-2 serotype (52.8%) was the most frequently observed, followed by DENV-1 (37.4%), and to a lesser extent DENV-3 (6.9%) and DENV-4 serotypes (2.9%) (Table 3). In most regions, we observed consistent circulation of one or more serotypes over time, with one serotype predominating over others; additionally, after

221	novel serotype introductions or reintroductions of a serotype that had not circulated at high rates for a
222	few years, we could observe displacement of one serotype by another. For example, in Loreto in 2007,
223	DENV-3 was the predominant circulating serotype; it was displaced by DENV-4 in 2008 until 2010,
224	and then after a brief period when DENV-1, DENV-2, and DENV-4 were co-circulating at the same
225	time, DENV-2 caused a dramatic outbreak and became the predominant serotype in the region for nearly
226	a decade (S1 Fig).

Table 3. Circulating dengue serotypes by region and year registered in the NETLAB-INS system from

2007 to 2022.


Regions	DENV-1	DENV-2	DENV-3	DENV-4	Total	Percent by region
Loreto	3,127	4,816	112	272	8,327	14.2%
San Martín	1,222	4,004	128	202	5,556	9.5%
Ucayali	881	3,345	128	160	4,514	7.7%
Junín	2,621	2,386	54	109	5,170	8.8%
Madre de Dios	1,787	2,177	271	237	4,472	7.6%
Cajamarca	1,315	1,980	394	54	3,743	6.4%
Lambayeque	206	1,707	719	81	2,713	4.6%
Piura	2,770	1,552	724	291	5,337	9.1%
Cusco	1,296	1,485	22	11	2,814	4.8%
Ayacucho	638	1,223	4	1	1,866	3.2%
Huánuco	869	1,194	31	64	2,158	3.7%
Tumbes	647	1,187	127	55	2,016	3.4%
Lima	1,619	927	418	52	3,016	5.1%
Ancash	1,793	897	17	5	2,712	4.6%
Ica	568	774	2	0	1,344	2.3%
La Libertad	346	738	803	59	1,946	3.3%
Amazonas	137	444	112	32	725	1.2%
Puno	46	141	1	0	188	0.3%
Pasco	64	56	5	6	131	0.2%
Total	21,952	31,033	4,072	1,691	59.749	1000/
N (%)	(37.4%)	(52.8%)	(6.9%)	(2.9%)	58,748	100%


When examining different combinations of serotypes, of the 304 region-years analyzed,
DENV-12 was the most commonly observed combination of circulating serotypes, which circulated in
74 region-years (24.3%), followed by DENV-2 (35 region-years), DENV-23 (29 region-years), DENV123 (27 region-years), and DENV-134 (26 region-years), while in 37 region-years (12.2%) no serotype
circulation was reported (S1 Table).

237 Serotype circulation attributed to severe dengue

Focusing on severe dengue cases alone, the highest frequency of reported SD cases occurred when there was circulation of DENV-12 (37%), followed by DENV-123 (19.7%) and DENV-23 (12.6%), noting that more SD cases were observed with the involvement of DENV-2 in some combination or alone (Fig 2).

242





245

243

246 Association between SD-DWS and serotype circulation

Table 4 presents results from our mixed negative binomial regression models for the association
between specific serotype circulation and the cumulative incidence of SD-DWS. In the adjusted model,
we observed that there is a higher risk for increased cumulative incidence of SD-DWS in regions where

250 DENV-1, DENV-2, and DENV-3 cocirculated (DENV-123); the average incidence ratio per 100,000 251 inhabitants increases by 7.6 times. Note that the circulating types of serotypes DENV-124, DENV-13, 252 DENV-24, DENV-3, DENV-34, DENV-234, DENV-14, and DENV-1234, were not included 253 in the adjusted model because they circulated infrequently (circulated in less than 6% of the study period, S1 Table) and because their inclusion yielded wide confidence intervals. However, in the 254 255 adjusted analysis, when all types of serotype circulation were included, the circulation of serotype 2 or 256 its combination showed a high-risk factor for the incidence of SD-DWS (S2 Table). Hence, we 257 conducted a separate analysis to evaluate the cumulative incidence risk of SD-DWS due to the 258 circulation of DENV-2 alone or in combination with other serotypes and found the average incidence 259 ratio per 100,000 inhabitants increases up to 27.7 times (Table 5).

260

 261
 Table 4. Association between specific serotype circulation and cumulative incidence of severe dengue

and/or dengue with warning signs.

	Cumulative Incidence of SD-DWS										
Variables	Cı	Crude bivariate analysis				Multivariate adjusted analysis				nalysis	
	IRRc		C 95		p p	-	IRRa		C 95		р
Circulation of DENV-123						-					
No	Ref.						Ref.				
Yes	3.17	1.55	-	6.50	0.002		7.57	4.00	-	14.31	< 0.001
Circulation of DENV-12											
No	Ref.						Ref.				
Yes	3.27	2.04	-	5.25	< 0.001		4.66	2.57	-	8.44	< 0.001
Circulation of DENV-23											
No	Ref.						Ref.				
Yes	1.22	0.58	-	2.57	0.599		3.55	1.75	-	7.21	< 0.001
Circulation of DENV-2											
No	Ref.						Ref.				
Yes	0.67	0.33	-	1.39	0.288		1.86	0.91	-	3.83	0.091
Circulation of DENV-1											
No	Ref.						Ref.				
Yes	0.07	0.02	-	0.21	< 0.001		0.22	0.07	-	0.66	0.007
Circulation of DENV-134											
No	Ref.						Ref.				
Yes	0.01	0.01	-	0.03	< 0.001		0.09	0.03	-	0.24	< 0.001
Poverty level at the regional level	0.85	0.81	-	0.89	< 0.001		0.93	0.89	-	0.97	0.001
Total primary health centers per total population per region	0.97	0.93	-	1.02	0.220		1.00	0.95	-	1.04	0.867

IRRc: Crude cumulative incidence ratios per 100,000 population. IRRa: Adjusted cumulative incidence ratios per 100,000 population. For repeated measures over time, a mixed negative binomial regression model was used.

Table 5: Association between the circulation of each serotype or its combination with the cumulative

005	1	C	1	1/	1	• . 1	•	•
265	incidence	of severe	dengue	and/or (denoue	with	warning	sions
200	menachee	01 56 616	acingue	und or v	acingue	** 1 1 1 1	warming	Signs.

	Cumulative Incidence of SD-DWS									
Variables	Crude bivariate analysis					Multivariate adjusted analysis				nalysis
	IRRc	Rc IC 95%		%	р	IRRa	IC 95%		%	р
Circulation of DENV-1 or its combination										
No	Ref.					Ref.				
Yes	2.19	1.39	_	3.44	3.444	2.34	1.61	_	3.41	< 0.001
Circulation of DENV-2 or its combination										
No	Ref.					Ref.				
Yes	51.51	31.35	-	84.62	< 0.001	27.70	15.46	-	49.63	< 0.001
Circulation of DENV-3 or its combination										
No	Ref.					Ref.				
Yes	0.99	0.59	-	1.66	0.966	1.53	0.98	-	2.38	0.063
Circulation of DENV-4 or its combination										
No	Ref.					Ref.				
Yes	0.22	0.12	-	0.40	< 0.001	0.72	0.43	-	1.22	0.225
Poverty level at the regional level	0.85	0.81	-	0.89	< 0.001	0.94	0.90	-	0.98	0.002
Total primary health centers per total population per region	0.97	0.93	-	1.02	0.220	0.98	0.93	-	1.03	0.330

IRRc: Crude cumulative incidence ratios per 100,000 population. IRRa: Adjusted cumulative incidence ratios per 100,000 population. A mixed negative binomial regression model was used for repeated measures over time.

266

267 Association between SD-DWS and poverty

We also observed that as regional poverty increased, the cumulative incidence of SD-DWS reduced between 6% (Table 5) and 7% (Table 4). Specifically, in regions with a high level of poverty, such as Loreto and Ucayali, there is a trend of lower cumulative incidence of DS-DWS, while in regions with a low level of poverty, there is a trend of increasing incidence of DS-DWS (S2 Fig.). To explore these results further, we categorized the poverty-level variables into tertiles and re-ran the main model. In this new analysis, we found that regions in the highest tertile (wealthier region) had up to 14.2 times more DS-DWS incidence than regions in the lowest tertile (Table S3).

276 **Discussion**

Our results suggest that the population rates of SD-DWS increase when DENV-2 is one of multiple co-circulating dengue virus serotypes in a region. These findings are consistent with previous studies in other countries that have evidenced a higher risk of severe dengue related to the circulation of the DENV-2 serotype [22–24].

281 Although our results indicate a higher risk of disease severity due to the presence of DENV-2, 282 we could not determine if this was due to the introduction of a novel genotype (Asian/American) and 283 Cosmopolitan genotypes) because genotyping is limited. Other studies from Peru, however, have 284 described increased disease severity associated with presentations of the 2010 introduction of 285 Asian/American DENV-2 to Iquitos [7,25–27]. The 2019 dengue outbreak in Madre de Dios coincided 286 with the entry of the Cosmopolitan genotype of DENV-2 as well [28]. In 2023, an unprecedented 287 outbreak in both size and areas affected had a particularly devastating impact on the northern coast of 288 Peru, with historic highs of reported SD cases and mortality; once again, it was the circulation of the 289 Cosmopolitan genotype of DENV-2 [2].

The lower cumulative incidence of SD-DWS observed in the context of DENV-1 circulation and the combination of DENV-134 provides additional support for the finding that serotype DENV-2, or its combination is a major risk factor for severe disease. It is important to note, however, that this observation is not equivalent to the conclusion that these other serotypes are protective against severe disease.

We showed that when regional poverty increased, the cumulative incidence of SD-DWS reduced by about 7%. Some studies have found that poor nutritional status can be protective against severe disease at the individual level [29,30]. Many host and environmental factors associated with poverty have multiple and complex impacts on dengue virus transmission, requiring detailed and longterm longitudinal research studies.

300 This study highlights the importance of diagnostic surveillance of circulating DENV serotypes.
301 As DENV expands to new areas of Peru, as has occurred recently, health personnel with no or limited
302 experience with dengue must be trained on its management and treatment. Shifts in DENV serotypes

or genotypes increase the risk of epidemic transmission because the population likely has lower levels
of immunity toward a serotype that has been absent for multiple years. Additionally, the increased risk
for severe diseases associated with DENV-2 is well established in cohort studies of individuals [22–
24], and our study validates this at the population level.

307 There are various limitations to this study. We used public data aggregated at the population 308 level and lacked detailed information on the identification of the circulating serotype (or its phenotypic 309 variants) for each dengue case reported by the epidemiological surveillance system or the identification 310 of the type of infection (first, second, third, or fourth) of each reported dengue case. The information 311 obtained about the diagnosed dengue cases comes from the CDC-Peru's epidemiological surveillance 312 system; reported by public and private health systems at all levels of care and based on the diagnostic 313 criteria established by the WHO in 2009 [15]. As a result, variability in the diagnosis/reporting of 314 dengue cases by health personnel is very likely; however, this would result in a non-differential bias, as 315 it would affect all dengue diagnostic groups and all study regions similarly [31]. Additionally, the 316 Peruvian dengue epidemiological surveillance is based on a passive surveillance system: this likely 317 results in underreporting of dengue cases and identification of the circulating serotype, either because 318 most dengue cases are asymptomatic (of every 5 people with dengue, only one person is symptomatic [32]) or due to lack of access to care in the health system (especially in the context of epidemic 319 320 outbreaks). Finally, an important limitation is that population-level variables that could influence the 321 disease severity have not been taken into account in this study, such as the population at risk of second 322 infections (risk factor for severe dengue at the individual level) or vector control actions carried out 323 regionally (street and home fumigation, water treatment, and breeding site collection campaigns), which 324 are known to help reduce transmission intensity during an epidemic outbreak.

325

328 Acknowledgments

329	We thank the National Institute of Health of the Peruvian Ministry of Health and the CDC-
330	Peru for sharing data from their epidemiological surveillance system for dengue.
331	
332	
333	Funding
334	This study is part of Jorge L. Cañari-Casaño PhD thesis in Epidemiological Research
335	Doctorate at Universidad Peruana Cayetano Heredia under FONDECYT/CIENCIACTIVA
336	scholarship EF033-235-2015 and supported by training grant D43 TW007393 awarded by the Fogarty
337	International Center of the US National Institutes of Health.
338	
339	Data Availability
340	The final dataset used is available on <u>https://doi.org/10.6084/m9.figshare.25336015.v4</u>
341	
342	
343	
344	
345	
346	
347	
348	
349	
350	

351 **References**


- Simmons CP, Farrar JJ, van Vinh Chau N, Wills B, Ham Tu B, Chi Minh City H.
 Dengue. New England Journal of Medicine [Internet]. 2012 Apr 12 [cited 2024 Apr
- 354 25];366(15):1423–32. Available from:
- 355 https://www.nejm.org/doi/full/10.1056/NEJMra1110265
- Cabezas Sánchez C, Cabezas Sánchez C. Dengue en el Perú: crónica de epidemias recurrentes (1990 -2023), el virus, el Aedes aegypti y sus determinantes, ¿a dónde vamos? Anales de la Facultad de Medicina [Internet]. 2023 Jul 1 [cited 2023 Nov
 6];84(2):145–8. Available from:
- 360 http://www.scielo.org.pe/scielo.php?script=sci_arttext&pid=S1025-
- 361 55832023000200145&Ing=es&nrm=iso&tIng=es
- César C, Fiestas V, García-Mendoza M, Palomino M, Mamani E, Donaires F. Dengue
 in peru: a quarter century after its reemergence. Rev Peru Med Exp Salud Publica
 [Internet]. 2015 Apr 2 [cited 2023 Aug 8];32(1):146–56. Available from:
- 365 https://rpmesp.ins.gob.pe/index.php/rpmesp/article/view/1587/1857
- Vazquez-Prokopec GM, Morrison AC, Paz-Soldan V, Stoddard ST, Koval W, Waller
 LA, et al. Inapparent infections shape the transmission heterogeneity of dengue.
 PNAS Nexus [Internet]. 2023 Mar 1 [cited 2024 Apr 25];2(3). Available from:
 /pmc/articles/PMC10003742/
- Liebman KA, Stoddard ST, Morrison AC, Rocha C, Minnick S, Sihuincha M, et al.
 Spatial dimensions of dengue virus transmission across interepidemic and epidemic
 periods in iquitos, peru (1999-2003). PLoS Negl Trop Dis. 2012 Feb;6(2).
- Morrison AC, Minnick SL, Rocha C, Forshey BM, Stoddard ST, Getis A, et al.
 Epidemiology of Dengue Virus in Iquitos, Peru 1999 to 2005: Interepidemic and
 Epidemic Patterns of Transmission. PLoS Negl Trop Dis [Internet]. 2010 May [cited
 2021 Jul 26];4(5). Available from: /pmc/articles/PMC2864256/
- Velazco SD, Solórzano VF, Maldonado MS, Lencinas CC, Vela VV, Flores CT, et al.
 Impacto de la epidemia de dengue con un nuevo linaje del DENV-2 genotipo
 Americano / Asiático en la demanda de servicios del Hospital de Apoyo de Iquitos
 "César Garayar García." Rev Peru Med Exp Salud Publica [Internet]. 2011 Mar 31
 [cited 2021 Jul 26];28(1):156–66. Available from:
- 382 https://rpmesp.ins.gob.pe/rpmesp/article/view/474
- Sangkawibha N, Rojanasuphot S, Ahandrik S, Viriyapongse S, Jatanasen S, Salitul V,
 et al. Risk factors in dengue shock syndrome: a prospective epidemiologic study in
 Rayong, Thailandi. The 1980 outbreak. Am J Epidemiol [Internet]. 1984 Nov 1 [cited
 2021 Jul 25];120(5):653–69. Available from:
- 387 https://academic.oup.com/aje/article/120/5/653/90744
- 388
 9. Guzmán M, Kourí G, Valdés L, Bravo J, Vázquez S, Halstead S. Enhanced severity of secondary dengue-2 infections: death rates in 1981 and 1997 Cuban outbreaks. Rev
 390 Panam Salud Publica [Internet]. 2002 [cited 2021 Jul 25];11(4):223–7. Available from: https://pubmed.ncbi.nlm.nih.gov/12049030/
- 392 10. Soo KM, Khalid B, Ching SM, Chee HY. Meta-Analysis of Dengue Severity during
 393 Infection by Different Dengue Virus Serotypes in Primary and Secondary Infections.
 394 PLoS One. 2016 May 1;11(5):e0154760.
- 395 11. Guzman MG, Alvarez M, Halstead SB. Secondary infection as a risk factor for dengue
 396 hemorrhagic fever/dengue shock syndrome: an historical perspective and role of

397		antibody-dependent enhancement of infection. Archives of Virology 2013 158:7
398		[Internet]. 2013 Mar 8 [cited 2023 Aug 8];158(7):1445–59. Available from:
399		https://link.springer.com/article/10.1007/s00705-013-1645-3
400	12.	Tsheten T, Clements A, Gray D, Adhikary R, Furuya-Kanamori L, Wangdi K. Clinical
401		predictors of severe dengue: a systematic review and meta-analysis. Infect Dis
402		Poverty [Internet]. 2021 Dec 1 [cited 2021 Oct 31];10(1). Available from:
403		https://pubmed.ncbi.nlm.nih.gov/34627388/
404	13.	Kanakaratne N, Wahala WMPB, Messer WB, Tissera HA, Shahani A, Abeysinghe N,
405	-	et al. Severe Dengue Epidemics in Sri Lanka, 2003–2006 - Volume 15, Number 2-
406		February 2009 - Emerging Infectious Diseases journal - CDC. Emerg Infect Dis
407		[Internet]. 2009 Feb [cited 2023 Aug 8];15(2):192–9. Available from:
408		https://wwwnc.cdc.gov/eid/article/15/2/08-0926_article
409	14.	Ministerio de Salud del Perú. Norma técnica de salud para la vigilancia
410	14.	epidemiológica Y diagnóstico de laboratorio de dengue, chikungunya, zika y otras
411		arbovirosis en el Perú [Internet]. 2017 [cited 2024 Mar 17]. Available from:
412		https://www.dge.gob.pe/portal/docs/tools/arbovirosis18.pdf
412	15	World Health Organization (WHO). Dengue guidelines for diagnosis, treatment,
	15.	
414 415		prevention and control [Internet]. Geneva; 2009 p. 1–147. Available from: www.who.int/tdr
415 416	16	
416	16.	Mamani E, Figueroa D, García MP, Garaycochea M del C, Pozo EJ. Infecciones
417		concurrentes por dos serotipos del virus dengue durante un brote en el noroeste de
418		Perú, 2008. Rev Peru Med Exp Salud Publica [Internet]. 2010 [cited 2024 Mar
419		17];27(1):16–21. Available from:
420		http://www.scielo.org.pe/scielo.php?script=sci_arttext&pid=S1726-
421	4 -	46342010000100004&Ing=es&nrm=iso&tIng=es
422	17.	Vargas-Herrera J, Segovia-Juarez J, Garro Nuñez GM. Sistema de información de la
423		red nacional de laboratorios de salud pública en el Perú (NETLAB). Rev Peru Med
424		Exp Salud Publica [Internet]. 2015 Jun 19 [cited 2024 Feb 23];32(2):378–84. Available
425		from: https://rpmesp.ins.gob.pe/index.php/rpmesp/article/view/1636/1817
426	18.	Ministerio de Salud del Perú. Portal del Estado Peruano - Portal de Transparencia del
427		Ministerio de Salud [Internet]. 2023 [cited 2024 Mar 17]. Available from:
428		https://transparencia.gob.pe/reportes_directos/pep_transparencia_acceso_informacio
429		n.aspx?id_entidad=143&id_tema=49&cod_rueep=0&ver=
430	19.	Instituto Nacional de Estadística e Informática - INEI Perú. Multidimensionalidad de la
431		Pobreza [Internet]. 2014 [cited 2024 Mar 17]. p. 83–96. Available from:
432		https://www.inei.gob.pe/media/MenuRecursivo/publicaciones_digitales/Est/Lib1306/ca
433		p04.pdf
434	20.	Ministerio de Salud del Perú. Norma Técnica: Categorías de establecimientos del
435		sector salud (NT Nº 021-MINSA/DGSP V.01) [Internet]. 2005 [cited 2024 Mar 17].
436		Available from: https://www.gob.pe/institucion/minsa/informes-publicaciones/352897-
437		categorias-de-establecimientos-del-sector-salud-nt-n-021-minsa-dgsp-v-01
438	21.	Salinas Ruíz J, Montesinos López OA, Hernández Ramírez G, Crossa Hiriart J.
439		Generalized Linear Mixed Models for Repeated Measurements. Generalized Linear
440		Mixed Models with Applications in Agriculture and Biology [Internet]. 2023 [cited 2024
441		Feb 23];377–423. Available from: https://link.springer.com/chapter/10.1007/978-3-
442		031-32800-8_9
443	22.	Balmaseda A, Hammond SN, Pérez L, Tellez Y, Saborío SI, Mercado JC, et al.
444		Serotype-specific differences in clinical manifestations of dengue. Am J Trop Med Hyg

445 [Internet]. 2006 Mar 1 [cited 2023 Aug 8];74(3):449-56. Available from: 446 https://www.ajtmh.org/view/journals/tpmd/74/3/article-p449.xml 447 23. Nisalak A, Endy TP, Nimmannitya S, Kalayanarooj S, Thisayakorn U, Scott RM, et al. 448 Serotype-specific dengue virus circulation and dengue disease in Bangkok, Thailand 449 from 1973 to 1999. Am J Trop Med Hyg [Internet]. 2003 Feb 1 [cited 2023 Aug 450 8]:68(2):191-202. Available from: https://www.ajtmh.org/view/journals/tpmd/68/2/article-p191.xml 451 452 24. Vicente CR, Herbinger KH, Fröschl G, Romano CM, Cabidelle A de SA, Junior CC. 453 Serotype influences on dengue severity: A cross-sectional study on 485 confirmed 454 dengue cases in Vitória, Brazil. BMC Infect Dis [Internet]. 2016 Jul 8 [cited 2023 Nov 455 6]:16(1):1–7. Available from: https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-016-1668-v 456 457 25. Mamani E, Álvarez C, García M. M, Figueroa D, Gatti M, Guio H, et al. Circulación de 458 un linaje diferente del virus dengue 2 genotipo América / Asia en la región amazónica 459 de Perú, 2010. Rev Peru Med Exp Salud Publica [Internet]. 2011 [cited 2023 Aug 8]:28(1):72-7. Available from: 460 461 http://www.scielo.org.pe/scielo.php?script=sci arttext&pid=S1726-462 46342011000100011&Ing=es&nrm=iso&tIng=es Williams M, Mayer S V., Johnson WL, Chen R, Volkova E, Vilcarromero S, et al. 463 26. 464 Lineage II of Southeast Asian/American DENV-2 is Associated with a Severe Dengue Outbreak in the Peruvian Amazon. Am J Trop Med Hyg [Internet]. 2014 Sep 3 [cited 465 2024 Apr 30];91(3):611-20. Available from: 466 467 https://www.ajtmh.org/view/journals/tpmd/91/3/article-p611.xml 468 Solórzano VF, Maldonado MS, Toscano FD, Velazco SD, María García M, Mamani E, 27. 469 et al. [Clinical characteristics of patients admitted to hospital "Cesar Garayar García", 470 Iquitos during the dengue epidemic, January-February 2011]. Rev Peru Med Exp Salud Publica [Internet]. 2011 [cited 2024 Apr 30];28(1):78-82. Available from: 471 472 https://pubmed.ncbi.nlm.nih.gov/21537773/ 473 Paquita García M, Padilla C, Figueroa D, Manrique C, Cabezas C. Emergencia del 28. 474 genotipo Cosmopolitan del virus dengue serotipo 2 (DENV2) en Madre de Dios, Perú, 475 2019. Rev Peru Med Exp Salud Publica [Internet]. 2022 Mar 17 [cited 2023 Aug 476 8];39(1):126-8. Available from: 477 https://rpmesp.ins.gob.pe/index.php/rpmesp/article/view/10861/4917 478 29. Chiu YY, Lin CY, Yu LS, Wang WH, Huang CH, Chen YH. The association of obesity 479 and dengue severity in hospitalized adult patients. Journal of Microbiology, 480 Immunology and Infection. 2023 Apr 1:56(2):267-73. 481 Chen CY, Chiu YY, Chen YC, Huang CH, Wang WH, Chen YH, et al. Obesity as a 30. 482 clinical predictor for severe manifestation of dengue: a systematic review and meta-483 analysis. BMC Infect Dis [Internet]. 2023 Dec 1 [cited 2023 Nov 24]:23(1). Available 484 from: https://pubmed.ncbi.nlm.nih.gov/37525106/ 485 31. Hernández-Avila M, Garrido F, Salazar-Martínez E. Sesgos en estudios 486 epidemiológicos. Salud Publica Mex. 2000 Jan;42(1):438-46. 487 32. Stoddard ST, Forshey BM, Morrison AC, Paz-Soldan VA, Vazquez-Prokopec GM, 488 Astete H, et al. House-to-house human movement drives dengue virus transmission. 489 Proc Natl Acad Sci U S A [Internet]. 2013 Jan 15 [cited 2023 Aug 8];110(3):994-9. 490 Available from: https://www.pnas.org/doi/abs/10.1073/pnas.1213349110 491


492 Supporting information

- 493 S1 Fig. Circulation proportion of dengue serotypes in Peru from 2007 to 2022.
- 494 S2 Fig. Trends and correlations between the cumulative incidence of SD-DWS per 100,000 inhabitants
- and poverty at the regional level from 2007 to 2022.
- 496 S1 Table. Serotype-specific circulation and severe dengue cases.
- 497 S2 Table. Association between all serotype-specific circulation types and cumulative incidence of SD-
- 498 DWS
- 499 S3 Table. Association between serotype-specific circulation types and cumulative incidence of SD-
- 500 DWS considering the poverty level variables as a categorical variable of poverty tertiles.



S1 Fig. Circulation proportion of dengue serotypes in Peru from 2007 to 2022.

S2 Fig: Trends and correlations between the cumulative incidence of DS-DWS per 100,000 inhabitants and poverty at the regional level from 2007 to 2022.



Trends and correlations between the cumulative incidence of DS-DWS per 100,000 inhabitants and poverty at the regional level from 2007 to 2022

Cumulative Incidence of SD-DWS per 100,000 inhabitants. Poverty rate at the regional level colour

Serotype-spec	cific circulation		egion-specific on of serotypes	Cases of severe dengue		
		n	Frequency	n	Frequency	
	DENV-1	19	6.3%	5	0.3%	
1	DENV-2	35	11.5%	91	4.7%	
1 serotype	DENV-3	4	1.3%	1	0.1%	
	DENV-4	3	1.0%	0	0.0%	
	DENV-12	74	24.3%	717	37.0%	
	DENV-13	6	2.0%	6	0.3%	
2	DENV-14	11	3.6%	29	1.5%	
2 serotypes	DENV-23	29	9.5%	244	12.6%	
	DENV-24	5	1.6%	163	8.4%	
	DENV-34	2	0.7%	0	0.0%	
	DENV-123	27	8.9%	382	19.7%	
2	DENV-124	9	3.0%	36	1.9%	
3 serotypes	DENV-134	26	8.6%	65	3.4%	
	DENV-234	1	0.3%	0	0.0%	
4 serotypes DENV-1234		16	5.3%	196	10.1%	
No circulation of serotypes		37	12.2%	4	0.2%	
Total		304	100.0%	1939	100.0%	

S1 Table: Serotype-specific circulation and severe dengue cases.

S2 Table: Association between all serotype-specific circulation types and cumulative incidence of SD-

DWS

	Cumulative Incidence of SD-DWS				
Variables	Multivariate adjusted analysis				
	IRRa	IC 95%		р	
Circulation of DENV-123	243.67	53.12	-	1117.71	< 0.001
Circulation of DENV-24	142.59	21.67	-	938.21	< 0.001
Circulation of DENV-12	128.99	29.07	-	572.31	< 0.001
Circulation of DENV-23	91.51	19.87	-	421.49	< 0.001
Circulation of DENV-124	57.64	10.43	-	318.60	< 0.001
Circulation of DENV-2	43.42	9.52	-	197.97	< 0.001
Circulation of DENV-1	7.59	1.41	-	40.76	0.018
Circulation of DENV-14	6.80	1.15	-	40.37	0.035
Circulation of DENV-134	2.97	0.56	-	15.79	0.201
Circulation of DENV-13	5.84	0.57	-	59.40	0.136
Circulation of DENV-4	0.00	0.00	-	0.00	1.000
Circulation of DENV-3	0.58	0.00	-	198.34	0.854
Circulation of DENV-34	1.49	0.01	-	154.60	0.867
Circulation of DENV-234	0.00	0.00	-	0.00	0.999
Circulation of DENV-1234	114.16	22.90	-	568.99	< 0.001
Poverty rate at the regional level	0.95	0.91	-	0.99	0.013
Total primary health centers over					
the total population at the	0.99	0.96	-	1.03	0.797
regional level					

IRRa: Adjusted cumulative incidence ratios per 100,000 population. A mixed negative binomial regression model was used for repeated measures over time.

S3 Table. Association between serotype-specific circulation types and cumulative incidence of DS-

DWS considering the poverty level variables as a categorical variable of poverty tertiles.

Variables	Multivariate adjusted analysis			
Variables	IRRa	IC 95%	р	
Circulation of DENV-123				
No	Ref.			
Yes	9.38	5.13 - 17.14	< 0.001	
Circulation of DENV-12				
No	Ref.			
Yes	5.90	3.53 - 9.86	< 0.001	
Circulation of DENV-23				
No	Ref.			
Yes	4.36	2.28 - 8.35	< 0.001	
Circulation of DENV-2				
No	Ref.			
Yes	1.94	1.01 - 3.73	0.047	
Circulation of DENV-1				
No	Ref.			
Yes	0.27	0.10 - 0.76	0.013	
Circulation of DENV-134				
No	Ref.			
Yes	0.11	0.04 - 0.28	< 0.001	
Poverty tercile at regional level				
1 (wealthier)	14.18	4.56 - 44.11	< 0.001	
2	8.97	4.09 - 19.66	< 0.001	
3 (poorer)	Ref.			
Total primary health centers over the total population at the regional level	1.00	0.95 - 1.04	0.867	

IRRa: Adjusted cumulative incidence ratios per 100,000 population. A mixed negative binomial regression model was used for repeated measures over time.